Is Teva’s downfall pharma’s Lavi moment?

If done right, Israel could turn the Teva crisis from a misfortune into an opportunity.

By
December 18, 2017 14:08
2 minute read.
Teva Pharmaceutical Industries workers block a road during a demonstration near the facility

Teva Pharmaceutical Industries workers block a road during a demonstration near the facility in Neot Hovav, southern Israel December 17, 2017. (photo credit: REUTERS/AMIR COHEN)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

In 1987, the Israeli cabinet decided in a controversial 12-11 vote to cancel the Lavi aircraft. Started five years earlier, the Lavi (Hebrew for “young lion”) was the most ambitious aircraft project undertaken by Israel, and led to the development of a multi-role, single-engine, fourth-generation fighter jet.

Over a billion dollars were spent on the Lavi’s development, and a number of prototypes were manufactured and flown. But despite its success, the government – under immense pressure from the United States – decided to shut down the project, opting instead to purchase more F-16s for the Israeli Air Force.

Be the first to know - Join our Facebook page.


While cancellation of the Lavi was a massive blow to Israel Aerospace Industries – which was forced to lay off more than a thousand engineers – five years of work on a combat jet provided Israel with unprecedented institutional knowledge. The engineers who worked on the Lavi had developed new and innovative radars, avionics, navigation systems and electronic warfare capabilities.

Thankfully, this did not go to waste. Instead, the talent captured by these engineers was picked up by other defense and hi-tech companies, and spread throughout Israel’s economy.
Teva workers strike outside the Knesset, December 2017

Two industries that benefited directly from the closure of the Lavi were Israel’s drone and satellite programs, both fields in which Israel is a world leader today. A year after the Lavi was shut down, for example, Israel launched its first satellite into space, becoming only the eighth country at the time to join the exclusive club of nations with the independent capability to do so.

It might be difficult to imagine this today, but the same could happen as a result of the current crisis with Teva. If done right, Israel could turn the Teva crisis from a misfortune into an opportunity.

While 1,750 employees face pink slips, there are – as Start-Up Nation Central, an NGO that tracks the Israeli hi-tech industry has found – over 100 pharmaceutical companies in Israel that could potentially pick up some of the ex-Teva employees.

A number of these companies are already positioned to absorb some of the Teva employees right away; others might need them to undergo new training. But what is really needed is for the Israeli start-up ecosystem to be flexible enough to not miss out on this pool of talent that will soon come streaming back into the workforce.

It would be a shame to let this expertise – built up over decades – go to waste. Let’s not miss out on what could be the Israeli pharma industry’s “Lavi moment.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The car in which MK Moshe Gafni was injured, September 17, 2018
September 18, 2018
Haredi MK Gafni nearly lynched on Yom Kippur eve for support of draft bill

By GIL HOFFMAN